Tumor Immunotherapy Medical Services in China

Immunotherapy for oncology represents a paradigm shift in cancer treatment, leveraging the body’s own immune system to recognize and eliminate malignant cells. Unlike conventional chemotherapy or radiation, which directly target tumors, immunotherapies—such as immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1 agents like pembrolizumab and nivolumab), CAR-T cell therapy, cancer vaccines, and cytokine-based regimens—enhance T-cell activation, overcome tumor-induced immunosuppressionitumor responses. This approach has demonstrated remarkable efficacy in advanced melanoma, non-small cell lung cancer, renal cell carcinoma, lymphomas, and certain hematologic malignancies, with some patients achieving long-term rem response varies by tumor type, biomarker status (e.g., PD-L1 expression, tumor mutational burden), and individual immune competence—making precise patient selection and multidisciplinary evaluation essential.

China has emerged as a leading destination for immunotherapy due to its robust clinical research infrastructure, rapid regulatory approval of novel agents—including domestically developed PD-1 inhibitors (e.g., camrelizumab, sintilimab) with comparable efficacy and favorable safety profiles—and widespread integration of next-generation sequencing and liquid biopsy for biomarker-guided treatment. Leading oncology centers in Beijing, Shanghai, and Guangzhou report high response rates in real-world cohorts, particularly in NSCLC and hepatocellular carcinoma, supported by state-of-the-art-cell analysis, and GMP-compliant CAR-T manufacturing facilities. Treatment costs are typically 40–60% lower than in the US or Western Europe, without compromising clinical rigor or regulatory oversight. As a dedicated medical tourism agency, we facilitate seamless access to these resources: coordinating appointments with NCCN- and E, verifying hospital accreditation and therapy eligibility, providing itemized, transparent pricing in advance, and delivering end assistance and medical translation to post-treatment follow-up coordination.

Medical Travel to China Guide: Cancer Immunotherapy (Oncology)

Visa & Entry: Most patients apply for an M (business) or L (tourist) visa; we assist with invitation letters from partner hospitals and streamline documentation. Entry requires a valid passport, completed visa application, and proof of onward travel.

Medical Insurance & Payment: International health insurance is rarely accepted in China; our agency provides transparent, all-inclusive pricing—covering consultations, immunotherapy (e.g., PD-1 inhibitors, CAR-T where approved), lab tests, and hospital fees—quoted upfront in USD/EUR. We coordinate direct payments to hospitals and offer flexible options: wire transfer, credit card (with processing fee), or third-party escrow.

Accommodation & Companions: We arrange certified medical apartments near top oncology centers (e.g., Peking Union Medical College Hospital, Fudan University Shanghai Cancer Center), including Wi-Fi, kitchen access, and 24/7 support. One companion may stay free of charge in patient rooms or at discounted rates in adjacent units.

Follow-Up Care: Post-treatment, our clinical coordinators schedule virtual check-ins every 2–4 weeks, share translated pathology reports and treatment summaries, and liaise with your local oncologist for seamless continuity of care—all included in our service package.